COMP <GO>
APVO vs DCOY // NET PROFIT MARGIN
Aptevo Therapeutics Inc. (NASDAQ) VS. Decoy Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: APVO 0
— DCOY 3
■ METRIC PARITY
LAST: $1.35 (+0.75%) • MKT CAP: $2.4M
net-margins
—
LAST: $1.03 (-3.27%) • MKT CAP: $2.6M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APVO VS. DCOY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APVO | DCOY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | DCOY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 28.0 | 36.7 | -8.70 | DCOY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.4M | $2.6M | -$137.6K | DCOY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APVO REV | DCOY REV | APVO GROSS % | DCOY GROSS % | APVO FCF | DCOY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $73.7M | $35.3M | — | — | -$25.6M | -$4.8M |
| FY 2024 | $68.9M | $16.1M | — | — | -$23.8M | -$4.5M |
| FY 2023 | $80.9M | $36.1M | — | — | -$11.7M | -$12.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APVO // BETA —
DCOY // BETA —